Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make treatment decisions using targeted therapies in clinical trials or FDA approved therapies, including "off-label" agents, that result in superior OS compared to historical outcomes for standard CUP therapy.
In order to participate you must meet the following criteria:
- Have a histologically or cytologically confirmed diagnosis of metastatic or advanced unresectable cancer of unknown primary including adenocarcinoma, poorly differentiated adenocarcinoma, poorly differentiated carcinoma, or squamous carcinoma.
- Have measurable disease.
- Are a first or second line patient with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2. Or, are a third line patient with an ECOG performance status score of 0 to 1.
Patients are considered potential candidates for treatment with targeted therapy.
This is a partial list of elgibility requirements.